Next step for Xenome
Thursday, 25 September, 2008
Privately held biotech Xenome has begun a Phase II trial of lead candidate Xen2174 for the control of acute post-operative pain.
The trial will enrol approximately 200 patients at multiple clinical sites in the US.
The aim is to evaluate the safety and efficacy of Xen2174 administered as a single intrathecal administration to patients undergoing unilateral bunionectomy, a standard model for the assessment of acute pain therapies.
Xenome is also in Phase II trials of Xen2174 for chronic pain.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
